OBJECTIVE: To examine the utility of single-photon emission computed tomography (SPECT) to predict conversion from mild cognitive impairment (MCI) to Alzheimer disease (AD). DESIGN: Longitudinal, prospective study. SETTING: University-based memory disorders clinic. PARTICIPANTS: One hundred twenty seven patients with MCI and 59 healthy comparison subjects followed up for 1-9 years. MEASUREMENTS: Diagnostic evaluation, neuropsychological tests, social/cognitive function, olfactory identification, apolipoprotein E genotype, magnetic resonance imaging, and brain Tc hexamethyl-propylene-aminoxime SPECT scan with visual ratings, and region of interest (ROI) analyses were done. RESULTS: Visual ratings of SPECT temporal and parietal blood flow did not distinguish eventual MCI converters to AD (N = 31) from nonconverters (N = 96), but the global rating predicted conversion (41.9% sensitivity and 82.3% specificity, Fisher's exact test p = 0.013). Blood flow in each ROI was not predictive, but when dichotomized at the median value of the patients with MCI, low flow increased the hazard of conversion to AD for parietal (hazard ratio: 2.96, 95% confidence interval: 1.16-7.53, p = 0.023) and medial temporal regions (hazard ratio: 3.12, 95% confidence interval: 1.14-8.56, p = 0.027). In the 3-year follow-up sample, low parietal (p <0.05) and medial temporal (p <0.01) flow predicted conversion to AD, with or without controlling for age, Mini-Mental State Examination, and apolipoprotein E ε4 genotype. These measures lost significance when other strong predictors were included in logistic regression analyses: verbal memory, social/cognitive functioning, olfactory identification deficits, hippocampal, and entorhinal cortex volumes. CONCLUSIONS: SPECT visual ratings showed limited utility in predicting MCI conversion to AD. The modest predictive utility of quantified low parietal and medial temporal flow using SPECT may decrease when other stronger predictors are available.
OBJECTIVE: To examine the utility of single-photon emission computed tomography (SPECT) to predict conversion from mild cognitive impairment (MCI) to Alzheimer disease (AD). DESIGN: Longitudinal, prospective study. SETTING: University-based memory disorders clinic. PARTICIPANTS: One hundred twenty seven patients with MCI and 59 healthy comparison subjects followed up for 1-9 years. MEASUREMENTS: Diagnostic evaluation, neuropsychological tests, social/cognitive function, olfactory identification, apolipoprotein E genotype, magnetic resonance imaging, and brain Tc hexamethyl-propylene-aminoxime SPECT scan with visual ratings, and region of interest (ROI) analyses were done. RESULTS: Visual ratings of SPECT temporal and parietal blood flow did not distinguish eventual MCI converters to AD (N = 31) from nonconverters (N = 96), but the global rating predicted conversion (41.9% sensitivity and 82.3% specificity, Fisher's exact test p = 0.013). Blood flow in each ROI was not predictive, but when dichotomized at the median value of the patients with MCI, low flow increased the hazard of conversion to AD for parietal (hazard ratio: 2.96, 95% confidence interval: 1.16-7.53, p = 0.023) and medial temporal regions (hazard ratio: 3.12, 95% confidence interval: 1.14-8.56, p = 0.027). In the 3-year follow-up sample, low parietal (p <0.05) and medial temporal (p <0.01) flow predicted conversion to AD, with or without controlling for age, Mini-Mental State Examination, and apolipoprotein E ε4 genotype. These measures lost significance when other strong predictors were included in logistic regression analyses: verbal memory, social/cognitive functioning, olfactory identification deficits, hippocampal, and entorhinal cortex volumes. CONCLUSIONS: SPECT visual ratings showed limited utility in predicting MCI conversion to AD. The modest predictive utility of quantified low parietal and medial temporal flow using SPECT may decrease when other stronger predictors are available.
Authors: B Borroni; D Anchisi; B Paghera; B Vicini; N Kerrouche; V Garibotto; A Terzi; L A Vignolo; M Di Luca; R Giubbini; A Padovani; D Perani Journal: Neurobiol Aging Date: 2005-03-24 Impact factor: 4.673
Authors: Eric M Reiman; Kewei Chen; Gene E Alexander; Richard J Caselli; Daniel Bandy; David Osborne; Ann M Saunders; John Hardy Journal: Proc Natl Acad Sci U S A Date: 2005-06-02 Impact factor: 11.205
Authors: M H Tabert; S M Albert; L Borukhova-Milov; Y Camacho; G Pelton; X Liu; Y Stern; D P Devanand Journal: Neurology Date: 2002-03-12 Impact factor: 9.910
Authors: D P Devanand; G Pradhaban; X Liu; A Khandji; S De Santi; S Segal; H Rusinek; G H Pelton; L S Honig; R Mayeux; Y Stern; M H Tabert; M J de Leon Journal: Neurology Date: 2007-03-13 Impact factor: 9.910
Authors: Marta Encinas; Ramón De Juan; Alberto Marcos; Pedro Gil; Ana Barabash; Cristina Fernández; Carmen De Ugarte; José Antonio Cabranes Journal: Eur J Nucl Med Mol Imaging Date: 2003-08-15 Impact factor: 9.236
Authors: Tomasz Gabryelewicz; Agnieszka Pawłowska-Detko; Jolanta Miśko; Jarosław B Cwikła; Anna Pfeffer; Anna Barczak; Bogusław Wasiak; Elzbieta Łuczywek; Leszek Królicki; Jerzy Walecki; Maria Barcikowska Journal: Med Sci Monit Date: 2007-05
Authors: Noble George; Emily G Gean; Ayon Nandi; Boris Frolov; Eram Zaidi; Ho Lee; James R Brašić; Dean F Wong Journal: CNS Drugs Date: 2015-04 Impact factor: 5.749
Authors: Ingrid Arevalo-Rodriguez; Nadja Smailagic; Marta Roqué I Figuls; Agustín Ciapponi; Erick Sanchez-Perez; Antri Giannakou; Olga L Pedraza; Xavier Bonfill Cosp; Sarah Cullum Journal: Cochrane Database Syst Rev Date: 2015-03-05
Authors: Markus Weih; Umüt Degirmenci; Sebastian Kreil; Piotr Lewczuk; Daniela Schmidt; Johannes Kornhuber; Torsten Kuwert Journal: Int J Alzheimers Dis Date: 2010-12-15